Physician profile
Karl W Siebe
NPI 1184699068
$6,509.30
in general payments reported to CMS, 2019-2025
27 companies · $1,166 in 2025
The $1,166 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $413 · 2021: $674 · 2022: $978 · 2023: $1,190 · 2024: $1,332 · 2025: $1,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,531 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,530.65 |
| Education | $157.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,569.44 | 2019-2025 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $961.98 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $703.64 | 2019-2025 | |
| Lilly USA, LLC | $421.27 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $415.41 | 2022-2025 | Sotyktu |
| Ucb, INC. | $379.53 | 2021-2025 | Bimzelx |
| Amgen INC. | $367.00 | 2019-2025 | Otezla |
| Leo Pharma INC. | $290.49 | 2021-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $162.33 | 2022-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $159.22 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $136.56 | 2021-2024 | Ilumya |
| Genentech USA, INC. | $122.05 | 2023-2024 | Erivedge, Actemra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $118.21 | 2019-2023 | Jublia |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.74 | 2022-2025 | Spevigo |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $89.71 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $76.20 | 2022-2025 | Nemluvio |
| Genzyme Corporation | $75.97 | 2020-2022 | |
| Mayne Pharma Commercial LLC | $52.26 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $49.25 | 2023-2025 | Zoryve |
| Incyte Corporation | $40.87 | 2023-2024 | Opzelura |
| Celgene Corporation | $36.17 | 2019 | |
| Journey Medical Corporation | $26.24 | 2024 | |
| Organon LLC | $17.39 | 2025 | Vtama |
| Dermira, INC. | $17.27 | 2019 | |
| Lnhc, INC | $14.99 | 2025 | Zelsuvmi |
| Almirall LLC | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Siebe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.